Extracted text (via pymupdf_layout)
5322 characters
International Genomics Consortium Presentation to Maricopa County Board of Supervisors April 24, 2017 1 IGC Track Record 1999 2002 2004 2006 2008 2010 2012 2016 2017 → Track record of innovation, scientific achievement, & job creation www.intgen.org | Page 2 Helped Envision and Drive TCGA The Cancer Genome Atlas (TCGA) project was inspired by and built on the success of IGC’s Expression Project for Oncology (expO) In collaboration with the National Cancer Institute, IGC served as the founding Biospecimen Core Repository (BCR) and primary Tissue Source Site Network for The Cancer Genome Atlas (TCGA) project. $74,400,000 in funding to IGC Many of the unique DNA & RNA extraction and high- throughput techniques were developed at IGC and transitioned into Paradigm 12 Nature publications so far www.intgen.org | Page 3 TCGA Impact 4 IGC’s Biospecimen Inventory (2017) Sample Type Current Inventory Frozen Cancer Tissue 18,358 Blood Derived Normal 25,114 FFPE Cancer Tissue 17,693 Normal Tissue 18,191 Total 79,356 www.intgen.org | Page 5 expO → TCGA → Redistribution www.intgen.org | Page 6 Paradigm Diagnostics Overview § The Paradigm Cancer Diagnostic (PCDx) was jointly developed as a non-profit joint venture from August 2012 through May of 2016 by $27.3 million contributed by the University of Michigan Health System and IGC expertise and leadership: o PCDx is the premier test to identify the best cancer treatments to enable progression free survival § Paradigm’s Rapid Development: o Groundbreaking independent prospective clinical study demonstrating the clinical utility of PCDx significantly improving progression free survival published on July 15, 2016 o 2016 commercial testing exceeded 1,000 patients and approached $4M in revenue including biopharma services. o Receiving over $2,500 / patient from payors and Medicare (compared to $1,200 for Foundation One) o Consolidated to the Phoenix Bioscience Center in March 2016 o Transitioned to a for-profit on June 1, 2016 to fund growth o $7M Series B Almost Fully Subscribed • Commencing Sales Volume Increase • Accelerating Registry Collaborations intgen.org | Page 7 The Paradigm Cancer Diagnostic (PCDx): Next Generation Sequencing Assay } Fast: Clinical report delivered in 3 to 5 business days ensures continuity and elevation of clinical care } Accurate: Average depth of coverage is >5,000x (less false positives and less false negatives) on 5% tumor. } Comprehensive: Analysis includes next generation sequencing (NGS) for mutations, gene fusions, copy number variations, mRNA expression and optional IHC for protein pathways & immune-checkpoint analysis } Clinically Proven: 76 + 12 combination therapies, NGS-based genomic analysis enables the significant multiplexing of biomarker targets. Supported by prospective clinical data. intgen.org | Page 8 Independent Prospective Validation Published July 15, 2016 RESPONDER DATA FROM IU COHORT PCDx Analytical Detection CNV or mRNA mRNA CNV or mRNA CNV/mRNA/DNA/IHC IHC mRNA or DNA IHC CNV or mRNA mRNA mRNA or DNA DNA CNV/mRNA/DNA/IHC CNV or mRNA CNV/mRNA/IHC CNV/mRNA mRNA CNV/mRNA/DNA/IHC CNV/mRNA mRNA IHC Summary of Findings: Most of the extraordinary responders used treatments identified by RNA. 43% treated with genomically guided therapy attained a PFS ratio ≥1.3 versus 5% treated with non-genomically guided therapy (p<0.0001). intgen.org | Page 9 9 Registry Initiated § 700 patients o Revenue generating cases ordered as part of standard of care o $20K initiation I see this as the future of oncology… I would o $252 per patient love to be involved at every level in the development to provide the clinical perspective. o $2,500 for publication o Average $284 / patient -Janakiraman Subramanian, MD § Up next: Crowd-sourced Paradigm Registry § Follow on site identified – www.intgen.org | Page 10 Updates § expO and TCGA were unprecedented success. Next steps o Biospecimen and knowledge redistribution through consulting (IGC as public utility) o Translational clinical diagnostics § Medical School and the Molecular Profiling Institute success. Next steps o Paradigm Diagnostics – the next generation of translational cancer testing o Paradigm Registry: Payor funded crowd sourced research collaboration impacting patient care § Maricopa funding has been essential o To assist with slim overhead rates on federal funding • Couldn’t have done expO or TCGA without the support • Currently supporting the NCI’s Clinical Proteomic Tumor Analysis Consortium (CP TAC) • Funding collections and outcomes from collaborating hospitals and for new grants o Helps maintain IGC in the Phoenix Bioscience Center • Where we continue to be a magnet for biotech and innovation www.intgen.org | Page 11 IGC Strategic Directions § Continue to Expand IGC’s Role as a Public Utility: o Redistribution of Large Well Characterized Cancer Biorepositories • Not a biospecimen jail o Driving Scientific, Medical and Economic Impact § Continue to Grow IGC as a Biosciences Innovation Core: o Collaborating closely with Maricopa County partners: ACA, ASU, AZ Oncology, Banner, Sonora Quest, Others o Driving Paradigm’s growth o ASU related initiatives o Opportunistic programs § 2017 Maricopa County Economic Impact Analysis and Publication / Press www.intgen.org | Page 12 www.intgen.org | Page 13